Improving the way we assign prostate cancer treatment

September 14, 2017
May-Britt Tessem's research group at the Norwegian University of Science and Technology has already discovered metabolic markers in blood that can separate prostate cancer from benign prostatic hyperplasia. Now the European Research Council has awarded Tessem a EUR 1.5 million grant to continue her research. Credit: Geir Otto Johansen, St. Olavs Hospital, Trondheim

Prostate cancer is the most common cancer among men in Europe. Every year around 5000 men in Norway are diagnosed with the disease.

Many different types of cannot be distinguished yet. Researchers have lacked the diagnostic tools to accurately differentiate the aggressive forms from the less aggressive types.

Some patients require aggressive treatment of the disease, but this isn't always necessary. The inability to assess the extent of the leads to many people being overtreated and subsequent suffering from unnecessary ailments.

A Trondheim-based research group at the Norwegian University of Science and Technology (NTNU) wants to do something about this. Researcher May-Britt Tessem is heading up the team, which is affiliated with the MR Cancer Group at NTNU's Department of Circulation and Medical Imaging.

The European Research Council, affiliated with the EU, is so impressed with the work of the Tessem Group that Tessem has been awarded a prestigious European Research Council (ERC) Starting Grant for her research on cancer.

Distinguishing high-risk cancer forms

Tessem is conducting basic research on prostate cancer. The research group is working on MR prostate imaging.

The group wants to find clinical diagnostic markers that can help prevent overtreatment with its attendant side effects and reduced quality of life. At the same time, the researchers hope to identify the most high-risk cases.

To this end, Tessem and her colleagues aim to provide information about the molecular signature of each patient.

New technology

In the research project supported by the EU, Tessem is shifting from studying one type of cancer in a cell line to retrieving tissue from prostate cancer patients in major tissue biobanks.

"To do this, we'll be using new and groundbreaking imaging technology, called 'multi-omics technology'," she said .

May-Britt Tessem, a researcher at the Norwegian University of Science and Technology, is working with tissue samples from a range of well-established Norwegian biobanks in her quest to better understand prostate cancer. Credit: Geir Otto Johansen, St. Olavs Hospital, Trondheim

The new technology enables a three-dimensional overview of the tissue and what it consists of.

The technology will be used on one and the same tissue sample from around 1000 patients. These samples come from high quality biobanks at NTNU and St. Olavs Hospital: MR Biobank, Biobank 1 and MRI-Guided Biopsies.

On the path to a solution

Tessem's group is building on one of its recent discoveries. The group has detected two metabolic biomarkers, which are substances in the body that can be analyzed and that tell us something about the condition of the body.

These two particular biomarkers can reveal information about prostate cancer. The biomarkers appear to determine whether prostate cancer patients are likely to relapse after surgery, so they can be important markers for aggressive prostate cancer.

The markers can make it easier to detect the life-threatening types of prostate cancer that require fast and personalized treatment. These can be detected before receiving treatment in an MRI scanner.

This method could become an important path to developing new medications.

The British Journal of Cancer has accepted and will soon publish the research group's findings.

Big consequences

The lack of good has major consequences. Patient exams involve a risk of infection, which is particularly problematic in patients with antibiotic resistance.

Currently, even men with a non-life-threatening form of prostate cancer have their prostate removed, receive radiation treatment and become sterilized from hormone treatment. We know that prostate treatment leaves many with a greatly reduced quality of life and significant side effects such as incontinence, erectile dysfunction and depression - in some cases ending in suicide.

Preventing overtreatment is thus a very important aspect of the group's goals.

Tessem is the fourth NTNU researcher in the Horizon 2020 research programme to receive this kind of ERC Starting Grant, and the first female. The funding of EUR 1.5 million will be spread over five years.

Explore further: Body size and prostate cancer risk

Related Stories

Body size and prostate cancer risk

July 14, 2017
Prostate cancer is the most common cancer in men in Europe and the second most frequently diagnosed cancer in men worldwide.

New findings concerning hereditary prostate cancer

July 11, 2016
It is a well-known fact that men with a family history of prostate cancer run an increased risk of developing the disease. The risk for brothers of men with prostate cancer is doubled. But a doubled risk of what, exactly? ...

Active surveillance for prostate cancer can give men good quality of life

March 14, 2016
Choosing ongoing monitoring instead of immediate curative treatment (surgery or radiotherapy) leads to a better overall quality of life for men with low-risk prostate cancer. In fact, the Quality of life (QoL) is about the ...

Are men with a family history of prostate cancer eligible for active surveillance?

April 6, 2017
Active surveillance—careful monitoring to determine if or when a cancer warrants treatment—is an increasingly prevalent choice for prostate cancer, but it's unclear if the strategy is appropriate for men with a family ...

Research breakthrough could lead to better prostate cancer treatment

November 19, 2015
Cancer researchers from the University of Glasgow and Royal Philips Cancer researchers have identified a gene which could help doctors to predict the aggressiveness of prostate cancer in patients.

What men should know about new prostate cancer screening guidelines

April 17, 2017
Men ages 55 to 69 should talk with their health care provider about prostate-specific antigen (PSA)-based screening for prostate cancer. That's according to new recommendations from the U.S. Preventive Services Task Force.

Recommended for you

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017
Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Brain cancer breakthrough could provide better treatment

September 19, 2017
A new discovery about the most common type of childhood brain cancer could transform treatment for young patients by enabling doctors to give the most effective therapies.

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.